Last reviewed · How we verify
NCT04012645: POSTER
Perfusion Outcomes With Near Infrared-Indocyanine Green Imaging System in Laparoscopic Total Mesorectal Excision for Mid- or Low-rectal CanceR
NA trial testing application of near infrared-indocyanine green imaging system in Rectal Neoplasms in 547 participants. Status unknown.
1 December 2023
Quick facts
| Lead sponsor | Zhongtao Zhang |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | diagnostic |
| Enrollment | 547 |
| Start date | 16 November 2023 |
| Primary completion | 1 December 2023 |
| Estimated completion | 1 December 2023 |
| Sites | 2 locations across China |
Drugs / interventions tested
- application of near infrared-indocyanine green imaging system
- Non-application of near infrared-indocyanine green imaging system
Conditions studied
- Rectal Neoplasms — all drugs for Rectal Neoplasms →
Sponsor
Zhongtao Zhang
Who can join
Adults 18 to 80, any sex, with Rectal Neoplasms. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
It is a multicenter, prospective, and randomized controlled clinical study of patients with mid- or low- rectal cancer who received laparoscopic TME surgery aims to explore whether the application of near infrared-indocyanine green imaging system can evaluate the anastomotic blood perfusion accurately, and optimize the surgical procedures, or even reduce the incidence rates of postoperative anastomotic leakage in mid- or low- rectal cancer patients.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Perfusion outcomes with near-infrared indocyanine green imaging system in laparoscopic total mesorectal excision for mid-rectal or low-rectal cancer (POSTER): a study protocol.
Sun L, Gao J, Wu G, Meng C, et al · · 2024 · cited 3× · PMID 38724058 · DOI 10.1136/bmjopen-2023-079858 -
Indocyanine Green Fluorescence Imaging for Colorectal Surgery: A Health Technology Assessment.
Ontario Health (Quality) . · · 2025 · cited 1× · PMID 40727261
Verify or expand the search:
- PubMed search for NCT04012645
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Rectal Neoplasms
Currently open trials in the same condition.
- NCT07522294 — Optimization and Standardization of Single-Port Robotic Transanal Minimally Invasive Surgery for Rectal Tumor Excision · NA · active not recruiting
- NCT07154173 — Comprehensive Analysis of Gut Microbiota Signatures in Metastatic Colorectal Cancer · recruiting
- NCT06442215 — Selection of Surgical Technique in Rectal Cancer · recruiting
- NCT06017583 — Neoadjuvant Chemotherapy With PD-1 Inhibitors Combined With SIB-IMRT in the Treatment of Locally Advanced Rectal Cancer · Phase 3 · recruiting
- NCT05943444 — Comparison of Postoperative Anal Function Between Parks and Bacon Techniques in Low Rectal Cancer · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04012645 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Zhongtao Zhang
- Last refreshed: 18 November 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04012645.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing